AVXL
Anavex Life Sciences Corp.
$3.07
-$0.02(-0.49%)
43
Overall
60
Value
27
Tech
--
Quality
Market Cap
$285.43M
Volume
719.72K
52W Range
$2.61 - $13.99
Target Price
$22.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Sep | 2017 Sep | 2018 Sep | 2019 Sep | 2020 Sep | 2021 Sep | 2022 Sep | 2023 Sep | 2024 Sep | 2025 Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $-5.8K | -- | $-30.9K | $-151.1K | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $-5.8K | -- | $-30.9K | $-151.1K | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $-5.8K | -- | $-30.9K | $-151.1K | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-15.6M | $-15.7M | $-19.3M | $-29.1M | $31.1M | $-42.0M | $51.0M | $55.8M | $52.9M | $51.4M | ||
| Research & Development | $7.3M | $10.7M | $13.3M | $22.3M | $25.2M | $33.0M | $37.9M | $43.7M | $41.8M | $37.6M | ||
| Research Expense | $7.3M | $10.7M | $13.3M | $22.3M | $25.2M | $33.0M | $37.9M | $43.7M | $41.8M | $37.6M | ||
| Selling, General & Administrative | $8.3M | $5.0M | $6.0M | $6.8M | $5.9M | $9.0M | $13.1M | $12.0M | $11.0M | $13.8M | ||
| General & Administrative Expenses | $8.3M | $5.0M | $6.0M | $6.8M | $5.9M | $9.0M | $13.1M | $12.0M | $11.0M | $13.8M | ||
| Salaries & Wages | $-5.1M | $-4.1M | $-5.5M | $-6.4M | -- | -- | $18.4M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $73.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-15.6M | $-15.7M | $-19.4M | $-29.3M | $-31.1M | $-42.0M | $-51.0M | $-55.8M | $-52.9M | $-51.4M | ||
| EBITDA | $-14.7M | $-13.4M | $-17.2M | $-26.2M | $-30.9M | $-37.6M | $-47.6M | $-54.0M | $-50.3M | $-51.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $-180.0K | $-26.3K | $-947.0K | $-6.5M | $-7.3M | $-4.7M | ||
| Intinc | $924.9K | $2.2M | $2.0M | $2.8M | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $924.9K | $2.2M | $2.0M | $2.8M | $180.0K | $26.3K | $-947.0K | $6.5M | $7.3M | $4.7M | ||
| Other Income/Expense | $-61.2K | -- | $-2.2M | $-115.8K | $-4.5M | $-4.6M | $2.4M | $2.7M | -- | -- | ||
| Other Special Charges | $61.2K | -- | $2.2M | $115.8K | $4.5M | $4.6M | $3.3M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-14.7M | $-13.4M | $-17.2M | $-26.2M | $-30.9M | $-37.6M | $-47.6M | $-54.0M | $-50.3M | $-51.1M | ||
| Pre-Tax Income | $-14.7M | $-13.4M | $-17.2M | $-26.2M | $-26.3M | $-37.6M | $-47.6M | $-47.5M | $-45.4M | $-47.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $29.6K | $59.6K | $72.7K | $82.2K | $22.7K | $268.0K | $358.0K | $7.0K | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-14.7M | $-13.5M | $-17.3M | $-26.3M | $-26.3M | $-37.9M | $-48.0M | $-47.5M | $-43.0M | $-46.4M | ||
| Net Income (Continuing Operations) | $-14.7M | $-13.5M | $-17.3M | $-26.3M | $-26.3M | $-37.9M | $-48.0M | $-47.5M | $-43.0M | $-46.4M | ||
| Net Income (Discontinued Operations) | $-14.7M | $-13.5M | $-17.3M | $-26.3M | $-26.3M | $-37.9M | $-48.0M | $-47.5M | $-43.0M | $-46.4M | ||
| Net Income (Common Stockholders) | $-14.7M | $-13.5M | $-17.3M | $-26.3M | $-26.3M | $-37.9M | $-48.0M | $-47.5M | $-43.0M | $-46.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-46.6M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-15.6M | $-15.7M | $-19.3M | $-29.1M | $31.1M | $-42.0M | $51.0M | $55.8M | $52.9M | $51.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $35.2M | $40.8M | $44.7M | $48.9M | $58.2M | $69.8M | -- | $79.2M | $83.5M | $85.3M | ||
| Average Shares Outstanding (Diluted) | $35.1M | $40.8M | $44.8M | $48.7M | $58.2M | $69.8M | -- | $79.2M | $83.5M | $85.3M | ||
| Shares Outstanding | $39.6M | $44.2M | $46.6M | $56.1M | $67.0M | $76.0M | $89.3M | $82.1M | $84.8M | $89.3M | ||
| Basic EPS | $-0.42 | -- | -- | -- | $-0.45 | $-0.54 | -- | $-0.60 | $-0.52 | $-0.54 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.45 | $-0.54 | -- | -- | $-0.52 | $-0.54 | ||
| Diluted EPS | $-0.42 | $-0.33 | $-0.39 | $-0.54 | $-0.45 | $-0.54 | -- | $-0.60 | $-0.52 | $-0.54 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | -- | $-0.52 | $-0.54 | ||
| OTHER METRICS | ||||||||||||
| Fees | $-5.8K | -- | $-30.9K | $-151.1K | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | $11.3K | $88.1K | $255.1K | $207.3K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $8.3M | $5.0M | $6.0M | $6.8M | $5.9M | $9.0M | $13.1M | $12.0M | $11.0M | $13.8M | ||
| Other Taxes | -- | -- | $-72.7K | $-82.2K | $22.7K | $267.6K | $358.0K | -- | -- | -- | ||
| Rent And Landing Fees | $8.3M | $5.0M | $6.0M | $6.8M | $233.4K | $130.8K | $72.9K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVXL | $3.07 | -0.5% | 719.72K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Anavex Life Sciences Corp. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW